Assessment of Consistency of Fixed Airflow Obstruction Status during Budesonide/Formoterol Treatment and Its Effects on Treatment Outcomes in Patients with Asthma

Tashkin, Donald P.; Moore, G.E.; Trudo, Frank; DePietro, Michael; Chipps, Bradley E.

doi:10.1016/j.jaip.2016.02.014

Cited by 10 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…ФОДП может развиваться у пациентов с длительным анамнезом БА вследствие ремоделирования бронхиальной стенки. Ремоделирование подразумевает под собой структурные изменения, такие как: увеличение массы гладких мышц, потеря целостности эпителия, утолщение базальной мембраны, субэпителиальный фиброз, гиперплазия подслизистой, снижение целостности хряща и повышение васкуляризации дыхательных путей [6]. Степень ремоделирования дыхательных путей положительно коррелирует с тяжестью заболевания [7].…”

Section: патофизиология фодпunclassified

“…В ряде исследований отмечается, что развитие ФОДП ассоциировано с худшим прогнозом течения БА [4][5][6]. Соответственно, необходимо выделить факторы риска, способствующие развитию ФОДП.…”

Section: факторы риска фодпunclassified

“…Среди предлагаемых причин развития ФОДП выделяют: неадекватное лечение, персистирующее воспаление дыхательных путей, нейтрофильное воспаление (нейтрофилы в индуцированной мокроте больше 65% [8]), которое может с трудом поддаваться лечению, а также возможное развитие стероидорезистентности [6]. Риск развития ФОДП возрастает в 2-4 раза у пациентов с повышенным содержанием эозинофилов в мокроте и/или периферической крови [12,19].…”

Section: факторы риска фодпunclassified

See 2 more Smart Citations

Modern understanding of bronchial asthma with fixed airflow obstruction

Kraposhina

Юрьевна²,

Собко

et al. 2021

Terapevticheskii arkhiv

View full text Add to dashboard Cite

The review provides data on one of the phenotypes of severe bronchial asthma it is asthma with fixed airway obstruction. According to data published today, there is no single pathway for the formation of fixed airway obstruction in patients with severe asthma. Increasing knowledge of the pathophysiology of fixed airway obstruction, as well as identifying the most significant risk factors, is essential for the successful treatment of such patients. In addition, the development of fixed obstruction is associated with a worse and sometimes fatal prognosis. Expanding the existing views is also necessary to overcome the difficulties of differential diagnosis between bronchial asthma with fixed airway obstruction and bronchial asthma in combination with COPD. All this will optimize the approach to the management of patients with bronchial asthma to prevent the formation of fixed airway obstruction.

show abstract

Section: патофизиология фодпunclassified

Section: факторы риска фодпunclassified

See 1 more Smart Citation

Modern understanding of bronchial asthma with fixed airflow obstruction

Kraposhina

Юрьевна²,

Собко

et al. 2021

Terapevticheskii arkhiv

View full text Add to dashboard Cite

show abstract

“…In addition, 16-25% and 33-43% of patients with well-established mild-to-moderate or moderate-to-severe asthma, respectively, have been shown to have a "fixed" component of airflow obstruction defined by an FEV 1 /FVC ratio < LLN or < 0.70 that fails to improve above the LLN or above 0.70 in response to a bronchodilator 32,33 , at least when tested on a single occasion. With therapy including inhaled glucocorticoids (ICS), full reversibility is restored in some, but not all, of these patients 34 .…”

Section: Differentiating Chronic Obstructive Pulmonary Disease From Amentioning

confidence: 99%

“…Although there is no real consensus regarding a definition of ACO, different groups have proposed diagnostic criteria [37][38][39][40] . A minor criterion in most of the proposed definitions is the presence of significant bronchodilator reversibility (≥ 12% and ≥ 200 ml increase in FEV 1 ) on 2 or more occasions and a major criterion is the presence of marked reversibility with bronchodilators (≥ 15% and ≥ 400 ml increase in FEV 1 ) [34][35][36][37] . A problem with the proposed minor criterion is that patients with well-defined COPD frequently exhibit this level of bronchodilator reversibility on ≥ 2 occasions 1,6,7 , while marked reversibility (the major criterion) is distinctly uncommon in COPD.…”

Section: Differentiating Chronic Obstructive Pulmonary Disease From Amentioning

confidence: 99%

Chronic Obstructive Pulmonary Disease and Bronchodilator Response: Does it Matter?

Tashkin¹

2018

BRN

Self Cite

View full text Add to dashboard Cite

A positive bronchodilator response is found in most patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD), although its presence varies over time within the same patient as well as across patients depending, in part, on the severity of the pre-bronchodilator level of airflow obstruction. Consequently, the response to a bronchodilator does not reliably distinguish COPD from asthma, although a particularly marked response suggests the presence of asthma/COPD overlap. The absence of an acute response to a bronchodilator in COPD does not preclude a favourable long-term response to maintenance bronchodilator therapy, although it may predict a reduced magnitude of the long-term response. Bronchodilator responsiveness does not appear to define a distinct phenotype of COPD or predict most clinically meaningful outcomes. However, performing spirometry after a bronchodilator may have practical utility in clinical practice as an indicator of the maximum ("ceiling") lung function that patients are capable of attaining as a goal to attempt to achieve with pharmacotherapy. (BRN Rev. 2018;4(3 ):200-13)Corresponding author: Donal P. Tashkin,

show abstract

Addition of long-acting beta2 agonists or long-acting muscarinic antagonists versus doubling the dose of inhaled corticosteroids (ICS) in adolescents and adults with uncontrolled asthma with medium dose ICS: a systematic review and network meta-analysis

Oba,

Anwer,

Patel

et al. 2023

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Plain language summary Summary of findings Background Description of the condition Description of the intervention How the intervention might work Why it is important to do this review Objectives Methods Criteria for considering studies for this review Search methods for identification of studies Data collection and analysis Results Description of studies Risk of bias in included studies Effects of interventions Discussion Summary of main results Overall completeness and applicability of evidence Quality of the evidence Potential biases in the review process Agreements and disagreements with other studies or reviews Authors' conclusions Acknowledgements Data and analyses Contributions of authors Contributions of editorial team Declarations of interest Sources of support Internal sources External sources Differences between protocol and review Characteristics of studies Characteristics of included studies [ordered by study ID] Characteristics of excluded studies [ordered by study ID] Characteristics of ongoing studies [ordered by study ID] Risk of bias Appendices Appendix 1. Database search strategy Appendix 2. Analysis Codes Appendix 3. Model fit parameters Appendix 4. Node-splitting results for severe exacerbations Appendix 5. Node-splitting results for moderate to severe exacerbations for grouped treatments Appendix 6. Node-splitting results for CFB in ACQ score at 3 months Appendix 7. Node-splitting results for CFB in ACQ score at 6 months. Appendix 8. Node-splitting results for CFB in ACQ scores at 12 months Appendix 9. Node-splitting results for CFB in AQLQ scores at 6 months Appendix 10. Node-splitting results for ACQ Response at 6 months Appendix 11. Node-splitting results for asthma-related SAEs Appendix 12. Node-splitting results for all-cause SAEs

show abstract

Assessment of Consistency of Fixed Airflow Obstruction Status during Budesonide/Formoterol Treatment and Its Effects on Treatment Outcomes in Patients with Asthma

Cited by 10 publications

References 19 publications

Modern understanding of bronchial asthma with fixed airflow obstruction

Modern understanding of bronchial asthma with fixed airflow obstruction

Chronic Obstructive Pulmonary Disease and Bronchodilator Response: Does it Matter?

Addition of long-acting beta2 agonists or long-acting muscarinic antagonists versus doubling the dose of inhaled corticosteroids (ICS) in adolescents and adults with uncontrolled asthma with medium dose ICS: a systematic review and network meta-analysis

Contact Info

Product

Resources

About